Sofosbuvir plus daclatasvir for post-transplant recurrent hepatitis C: Potent antiviral activity but no clinical benefit if treatment is given late
Titel:
Sofosbuvir plus daclatasvir for post-transplant recurrent hepatitis C: Potent antiviral activity but no clinical benefit if treatment is given late
Auteur:
Pellicelli, Adriano M. Montalbano, Marzia Lionetti, Raffaella Durand, Christine Ferenci, Peter D’Offizi, Gianpiero Knop, Viola Telese, Andrea Lenci, Ilaria Andreoli, Arnaldo Zeuzem, Stefan Angelico, Mario